{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:16:57Z","timestamp":1794493017170,"version":"4.9.1"},"reference-count":42,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, demonstrated efficacy over 48\u2009weeks in patients with alopecia areata (AA) in the ALLEGRO phase 2b\/3 study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This post hoc analysis evaluated individual Severity of Alopecia Tool (SALT) score trajectories in patients who received ritlecitinib 50\u2009mg and rolled over from Phase 2b\/3 into the ongoing, open\u2010label, Phase 3 ALLEGRO\u2010LT study to describe long\u2010term response patterns and associated baseline disease characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients aged \u226512\u2009years with \u226550% scalp hair loss received ritlecitinib 50\u2009mg once daily in both studies. SALT score trajectories from baseline to Month 24 were used to categorise patients as early (SALT score \u226420 at Week 24 and Months 12 and 24), middle (\u226420 at Months 12 and 24) or late responders (\u226420 by Month 24) or as partial responders (maintained 30% improvement), relapsers (achieved but did not maintain 30% improvement) or non\u2010responders (did not achieve 30% improvement). The proportions of patients achieving sustained response (achieved and maintained SALT score \u226420 at all subsequent available time points through Month 24) and complete response (SALT score 0 at \u22651 time point through Month 24) were evaluated. Multivariable logistic regression assessed variables associated with response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 191 patients treated with ritlecitinib 50\u2009mg, 87 (45.5%) were responders (SALT score \u226420), 24 (12.6%) were partial responders, 24 (12.6%) were relapsers and 56 (29.3%) were non\u2010responders. Of 87 patients categorised as responders, 81 (93.1%) sustained their clinical response and 47 (46.0%) achieved complete response. Factors associated with treatment response included female sex and less extensive and shorter duration of hair loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Approximately 45% of patients were SALT score responders, with up to 11% requiring &gt;1\u2009year of ritlecitinib treatment to achieve response, highlighting the importance of extended treatment duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      Registration\n                    <\/jats:title>\n                    <jats:p>ALLEGRO phase 2b\/3 study (NCT03732807); ALLEGRO\u2010LT study (NCT04006457).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.20547","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T23:41:42Z","timestamp":1739835702000},"page":"1163-1173","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the\n                    <scp>ALLEGRO<\/scp>\n                    clinical development programme"],"prefix":"10.1111","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4576-4616","authenticated-orcid":false,"given":"B.","family":"King","sequence":"first","affiliation":[{"name":"Dermatology Physicians of Connecticut  Fairfield Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mirmirani","sequence":"additional","affiliation":[{"name":"The Permanente Medical Group  Vallejo California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5219-9803","authenticated-orcid":false,"given":"K.","family":"Lo Sicco","sequence":"additional","affiliation":[{"name":"The Ronald O. Perelman Department of Dermatology New York University Grossman School of Medicine  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Ramot","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hadassah Medical Center  Jerusalem Israel"},{"name":"The Faculty of Medicine Hebrew University of Jerusalem  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6751-1428","authenticated-orcid":false,"given":"R.","family":"Sinclair","sequence":"additional","affiliation":[{"name":"Sinclair Dermatology  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Asfour","sequence":"additional","affiliation":[{"name":"The Dermatology Centre Salford Royal Hospital  Salford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5468-4589","authenticated-orcid":false,"given":"K.","family":"Ezzedine","sequence":"additional","affiliation":[{"name":"Department of Dermatology Henri Mondor University Hospital and EpiDermE  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Paul","sequence":"additional","affiliation":[{"name":"Department of Dermatology Toulouse University and CHU  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ohyama","sequence":"additional","affiliation":[{"name":"The Department of Dermatology Kyorin University Faculty of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. A.","family":"Edwards","sequence":"additional","affiliation":[{"name":"Health Services Consulting Corporation  Boxborough Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bonfanti","sequence":"additional","affiliation":[{"name":"Engineering Ingegneria Informatica  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Kerkmann","sequence":"additional","affiliation":[{"name":"Pfizer Pharma GmbH  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Wajsbrot","sequence":"additional","affiliation":[{"name":"Pfizer, Inc  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ishowo\u2010Adejumo","sequence":"additional","affiliation":[{"name":"Pfizer, Inc  Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. H.","family":"Zwillich","sequence":"additional","affiliation":[{"name":"Pfizer, Inc  Groton Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lejeune","sequence":"additional","affiliation":[{"name":"Pfizer, Inc  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.10.014"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.032"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12941"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.008"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.0002"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.04.035"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.01.048"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.086"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.6085"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14155"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1087-0024.2003.00807.x"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.04.004"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S172638"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31942"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02342"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aad7279"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02847"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1243556"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110343"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.9b00188"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00222-2"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad253"},{"key":"e_1_2_14_24_1","unstructured":"Clinical.trials.gov.PF\u201006651600 for the Treatment of Alopecia Areata (ALLEGRO\u20102b\/3).2018Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03732807"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae365"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad239"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.10.031"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2010.01135.x"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.03.036"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.4103\/0974-7753.66920"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.09.007"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.11"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c3671"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S10182"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01033-8"},{"key":"e_1_2_14_36_1","doi-asserted-by":"crossref","unstructured":"KingB BergfeldW BrzewskiP AskinO PasseronT RandhawaS et\u00a0al.Impact of disease history on the efficacy of ritlecitinib (PF\u201006651600) in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b\/3 study. 31st Annual Meeting of the European Academy of Dermatology and Venereology (EADV).2022.","DOI":"10.25251\/skin.6.supp.101"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19768"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.3049"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.07.013"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01676.x"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00711-3"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac050"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-024-00846-3"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.20547","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T07:48:38Z","timestamp":1748245718000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.20547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1111\/jdv.20547"],"URL":"https:\/\/doi.org\/10.1111\/jdv.20547","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"2024-05-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}